TY - JOUR T1 - Clinical Advantage of Attaining Index-Based Remission Prior to Composite Remission in Treating Rheumatoid Arthritis JO - Reumatología Clínica T2 - AU - Yoshii,Ichiro AU - Chijiwa,Tatsumi AU - Sawada,Naoya SN - 1699258X M3 - 10.1016/j.reuma.2021.09.008 DO - 10.1016/j.reuma.2021.09.008 UR - https://www.reumatologiaclinica.org/es-clinical-advantage-attaining-index-based-remission-articulo-S1699258X21002357 AB - Background and objectivesThe clinical advantage of targeting index-based remission prior to Boolean remission was evaluated retrospectively. Materials and methodsA total of 578 patients with rheumatoid arthritis (RA), who were treated for more than three years, were recruited. Patients who were treated to targeted index-based remission and composite measure remission criteria such as Boolean remission from the first consultation were divided according to the turn of attaining Boolean remission and index-based remission: G-IBR, a group that matched index-based remission at the same time Boolean remission is attained or earlier; G-BR_IF, a group that attained Boolean remission followed by index-based remission or failed; G-IR_BF, a group that could not attain Boolean remission despite attaining index-based remission; G-BothF, a group that failed to attain either Boolean remission or index-based remission. Background factors were statistically compared among groups. The Boolean remission rate in patients who attained index-based remission (BRR) and the rate of failure to attain index-based remission in patients who failed to attain Boolean remission (BFR) were statistically evaluated. ResultsGroups comprising 225, 231, and 482 in G-IBR; 160, 154, and 8 in G-BR_IF; 18, 18, and 75 in G-IR_BF; and 175, 175, and 13 in G-BothF when indexing the clinical disease activity index (CDAI), simplified disease activity index (SDAI), and 28-joints disease activity score with C-reactive protein (DAS28-CRP), respectively. Disease activity indices’ scores after Boolean remission were demonstrated to be significantly higher in the G-BR_IF group than in the G-IBR group. BRR was 92.6%, 92.8%, and 86.5%, while BFR was 71.3%, 71.3%, and 13.8% when indexing CDAI, SDAI, and DAS28-CRP, respectively. ConclusionsTargeting CDAI and SDAI remission prior to Boolean remission contributes to a stable clinical course. ER -